Schedule Today
(800)-221-4291

Same Day Service

DOT Drug Testing Locations Abo, NM

Our Local DOT Drug testing facilities in Abo, NM and the surrounding areas provide DOT Drug Testing, DOT Alcohol Testing, DOT Physicals, Consortium enrollment and other DOT services for Employers, Single operators and all DOT modes who are required to comply with 49 CFR Part 40 in Abo, NM including FMCSA, FTA, FAA, USCG, FRA and PHMSA . Testing centers are within minutes of your home or office and same day service is available in most cases.

“When you need a test, choose the best”

(800) 221-4291

Schedule Your Test

How to schedule a DOT drug test in Abo, NM

To schedule any type of DOT drug test or alcohol test in Abo, NM call our local scheduling department at (800) 221-4291. You may also schedule your DOT drug test online utilizing our express scheduling registration system by selecting your test and completing the Donor Information/Registration Section. You must register for the test prior to proceeding to the testing center.

The zip code you enter will be used to determine the closest DOT drug or DOT alcohol testing center which performs the type of test you have selected. A donor pass/registration form with the local testing center address, hours of operation and instructions will be sent to the e-mail address you provided. Take this form with you or have it available on your smart phone to provide to the testing center. No appointment is necessary in most cases. However, you must complete the donor information section and pay for the test at the time of registration.

Our laboratories are SAMHSA certified and all test results are verified by our in-house licensed physicians who serve as Medical Review Officers (MRO).

In addition to providing DOT drug testing and DOT breath alcohol testing in Abo, NM , Accredited Drug Testing also has additional testing centers throughout the metropolitan area and surrounding cities.

On the road or on vacation, no worries, Accredited Drug Testing has over 20,000 testing centers in all cities Nationwide and we can schedule your test, ANYWHERE, ANYTIME!

(800) 221-4291

Schedule Your Test

What are the DOT drug testing requirements?

In 1991, the Omnibus Transportation Employee Testing Act created the following DOT Agencies which established drug and alcohol testing regulations to ensure that aircraft, trains, trucks, and buses were operated in a safe and responsible manner. As an employer or individual operating in a “Safety Sensitive” position, it is important to understand how these regulations impact you.

49 CFR Part 40 (commonly known as “part 40”) explains:

Each DOT Agency and the USCG have specific regulations that cover:

FMCSA Drug and Alcohol Clearinghouse

The Federal Motor Carrier Safety Administration (FMCSA) amended its rule that would establish requirements for commercial driver’s license employers and individuals with regards to the drug and alcohol clearing house which will take affect on January 6, 2020.

The FMCSA Clearinghouse is a secure online database that will allow employers, the FMCSA, State Driver Licensing Agencies, State Law Enforcement and individual CDL operators to access real time important information about a CDL Driver’s drug and alcohol program violations and the ultimate goal of this database is to enhance safety on our Nation’s public roadways.

For specific requirements, click the appropriate agency listed below in which you or your company is regulated by. Ask about our DOT Complete Compliance Package!

The Opioid Overdose Crisis

Every day, more than 130 people in the United States die after overdosing on opioids. The misuse of and addiction to opioids—including prescription pain relievers, heroin, and synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as social and economic welfare. The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to prescription opioid pain relievers, and healthcare providers began to prescribe them at greater rates. This subsequently led to widespread diversion and misuse of these medications before it became clear that these medications could indeed be highly addictive.3,4 Opioid overdose rates began to increase. In 2017, more than 47,000 Americans died as a result of an opioid overdose, including prescription opioids, heroin, and illicitly manufactured fentanyl, a powerful synthetic opioid.1That same year, an estimated 1.7 million people in the United States suffered from substance use disorders related to prescription opioid pain relievers, and 652,000 suffered from a heroin use disorder (not mutually exclusive)

DOT Compliance Checklist in Abo, NM

DOT 49 CFR Part 40 Requirements for Safety Sensitive Employees.
(FMCSA-FAA-USCG-FRA-PHMSA-FTA)

* In addition, any company which employs 2 or more covered employees must have a written drug and alcohol policy and all supervisors must complete the DOT Supervisor Reasonable Suspicion Training. (Click here to learn more about our online training programs)

If a DOT covered employee or company does not have a copy of the original pre-employment drug test with a negative result, then a new DOT pre-employment drug test must be conducted, and the result maintained on file.

The department of transportation (DOT) requires that all DOT regulated “safety sensitive” employees have on file a negative DOT pre-employment drug test result and be a member of a DOT approved random selection consortium. In addition, if a DOT regulated company has more than one “safety sensitive” employee, the employer must also have a written DOT drug and alcohol policy and an on-site supervisor must have completed supervisor training for reasonable suspicion of illegal drug use or impairment.

To be compliant with DOT regulations, a company’s DOT drug and alcohol testing program must have the following components. Failing to comply can result in significant fines and penalties.

(800) 221-4291

Schedule Your Test

What is a DOT Drug Test in Abo, NM ?

On January 1, 2018 the Department of Transportation (DOT) issued a new rule which altered the DOT 5 panel urine test. Employers and individuals should be aware that the current DOT drug test is still a urine drug test, collected by qualified collectors, analyzed at a SAMHSA certified laboratory and reviewed by a licensed Medical Review Officer. Below you will find a list of the drugs that are screened for in the DOT 5 panel urine drug test:

When you need a test, choose the best!

DOT Drug Testing Services Abo, NM

(800)221-4291

For more information regarding the effects of drug abuse – Click Here

For more information on a drug free work place – Click Here

Local Area Info: ABO (gene)

Histo-blood group ABO system transferase is an enzyme with glycosyltransferase activity, which is encoded by the ABO gene in humans. It is ubiquitously expressed in many tissues and cell types. ABO determines the ABO blood group of an individual by modifying the oligosaccharides on cell surface glycoproteins. Variations in the sequence of the protein between individuals determine the type of modification and the blood group. The ABO gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.

The ABO gene resides on chromosome 9 at the band 9q34.2 and contains 7 exons. The ABO locus encodes three alleles. The A allele produces ?-1,3-N-acetylgalactosamine transferase (A-transferase), which catalyzes the transfer of GalNAc residues from the UDP-GalNAc donor nucleotide to the Gal residues of the acceptor H antigen, converting the H antigen into A antigen in A and AB individuals. The B allele encodes ?-1,3-galactosyl transferase (B-transferase), which catalyzes the transfer of Gal residues from the UDP-Gal donor nucleotide to the Gal residues of the acceptor H antigen, converting the H antigen into B antigen in B and AB individuals. Remarkably, the difference between the A and B glycosyltransferase enzymes is only four amino acids. The O allele lacks both enzymatic activities because of the frame shift caused by a deletion of guanine-258 in the gene which corresponds to a region near the N-terminus of the protein.This results in a frameshift and translation of an almost entirely different protein. This mutation results in a protein unable to modify oligosaccharides which end in fucose linked to galactose. Thus no A or B antigen is found in O individuals. This sugar combination is termed the H antigen. These antigens play an important role in the match of blood transfusion and organ transplantation. Other minor alleles have been found for this gene.

In human cells, the ABO alleles and their encoded glycosyltransferases have been described in several oncologic conditions. Using anti-GTA/GTB monoclonal antibodies, it was demonstrated that a loss of these enzymes was correlated to malignant bladder and oral epithelia. Furthermore, the expression of ABO blood group antigens in normal human tissues is dependent the type of differentiation of the epithelium. In most human carcinomas, including oral carcinoma, a significant event as part of the underlying mechanism is decreased expression of the A and B antigens. Several studies have observed that a relative down-regulation of GTA and GTB occurs in oral carcinomas in association with tumor development. More recently, a genome wide association study (GWAS) has identified variants in the ABO locus associated with susceptibility to pancreatic cancer.